atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure

Emerg Infect Dis. 2022 May;28(5):1062-1064. doi: 10.3201/eid2805.212517.

Abstract

We report the emergence of an atpE mutation in a clinical Mycobacterium tuberculosis strain. Genotypic and phenotypic bedaquiline susceptibility testing displayed variable results over time and ultimately were not predictive of treatment outcome. This observation highlights the limits of current genotypic and phenotypic methods for detection of bedaquiline resistance.

Keywords: MDR TB; Rv0678; XDR TB; antimicrobial resistance; atpE; bacteria; bedaquiline; tuberculosis; tuberculosis and other mycobacteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Diarylquinolines / pharmacology
  • Diarylquinolines / therapeutic use
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Mycobacterium tuberculosis* / genetics
  • Treatment Failure
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • bedaquiline